Figure 5.

SBP-101-treated VDID8⁺ mice (n = 10) show a delay in tumor progression and a decrease in overall tumor burden that is correlated with an increase in median survival. Female C57Bl/6 mice were injected with 250,000 VDID8⁺ mouse ovarian surface epithelial cells and subsequently treated with 24 mg/kg SBP-101 (3× per week, alternating weeks, three cycles). The median survival for treated mice was 65.5 days, while the median survival for untreated mice was 46 days (A). Untreated mice produced measurable ascites prior to treated mice, and the overall volume of ascites in untreated mice was larger (B). Using ascites as a measure of tumor burden, mice treated with SBP-101 were delayed in tumor formation and exhibited an overall decrease in tumor burden.